In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://abbv-744-in-acute-myeloid00134.blogsmine.com/32418233/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work